To see this page, please, enable javaScript and styleSheets on your browser: Tools -> Internet Options ...
Reload !
Gene AURKBTABLE OF CONTENTS / OPEN CLOSE ALL PARAGRAPHS
Summary back to top
Compact gene diagram back to top
340 supporting clones for gene AURKB back to top
cDNA accession
Links to the sequence
Tissue

most 5' clones
in red
Match
mRNA
From bp
to bp
in mRNA
From bp
to bp
in accs.
Clone encodes
complete protein
(with AA variation)
Features Anomalies
detected by
AceView
Accession
match over
(% length)
Base differences
relative to genome
(% identity)
CR605805 T cells (Jurkat cell line) Cot10-normalized .a 1 to 1227 1 to 1227 exact tiling clone,   1227/1227
(100 %)
0 diff
(100 %id)
BX362458   .a 1 to 811 1 to 810   fully sequenced,   810/810
(100 %)
5 diff
(99.4 %id)
BM555464 duodenal adenocarcinoma, cell line, small intestine .a 2 to 312 1 to 311       311/1214
(25 %)
2 diff
(99.9 %id)
BU187616 eye, retinoblastoma .a 10 to 893 36 to 920       885/920
(96 %)
12 diff
(98.7 %id)
BI117331 lung, small cell carcinoma .a 14 to 678 1 to 665       665/670
(99 %)
2 diff
(99.8 %id)
BG503280 embryonal carcinoma, testis .a 17 to 718 1 to 709       709/857
(82 %)
14 diff
(98.4 %id)
CD048309 embryonic stem cells, WA01, passage 38 .a 18 to 786 23 to 797       775/935
(82 %)
18 diff
(98.1 %id)
CD049970 embryonic stem cells, WA01, passage 38 .a 18 to 881 19 to 882       864/883
(97 %)
9 diff
(99.0 %id)
BM765420 stomach .a 19 to 676 1 to 658       658/658
(100 %)
4 diff
(99.4 %id)
BG530441 embryonal carcinoma, testis .a 23 to 698 1 to 681       681/681
(100 %)
7 diff
(99.0 %id)
AK314889   .a 24 to 1129 1 to 1106       1106/1106
(100 %)
3 diff
(99.8 %id)
BG685832 B-cells, primary B-cells from tonsils (cell line) .a 24 to 825 1 to 806       806/806
(100 %)
12 diff
(98.6 %id)
BM788554 stomach .a 24 to 665 1 to 642       642/642
(100 %)
0 diff
(100 %id)
CB141171 Liver .a 25 to 665 1 to 641       641/641
(100 %)
2 diff
(99.7 %id)
CD048934 embryonic stem cells, WA01, passage 38 .a 26 to 848 26 to 852       827/864
(95 %)
11 diff
(98.8 %id)
BU159806 eye, retinoblastoma .a 27 to 883 1 to 869       869/869
(100 %)
14 diff
(98.4 %id)
AL530215 brain, neuroblastoma cells, Neuroblastoma Cot 50-normalized .a 32 to 1108 1 to 1060       1060/1073
(98 %)
33 diff
(97.0 %id)
BX345090 Neuroblastoma Cot 50-normalized .a 32 to 933 1 to 894       894/911
(98 %)
17 diff
(98.2 %id)
BX366101 Neuroblastoma Cot 50-normalized .a 32 to 862 1 to 830       830/830
(100 %)
7 diff
(99.2 %id)
BM043467 carcinoma, cell line, Prostate .a 32 to 856 1 to 833       833/833
(100 %)
21 diff
(97.5 %id)
CN286700 embryonic stem cells, DMSO-treated H9 cellline .a 33 to 776 1 to 744       744/747
(99 %)
6 diff
(99.2 %id)
CR603941 Neuroblastoma Cot 50-normalized .a 33 to 1231 1 to 1199       1199/1199
(100 %)
0 diff
(100 %id)
BC000442 Lung, small cell carcinoma .a 34 to 1261 1 to 1228   tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 1228/1228
(100 %)
2 diff
(99.9 %id)
BE798853 lung, small cell carcinoma .a 34 to 732 36 to 733       698/733
(95 %)
6 diff
(99.2 %id)
BU855266 ovary, teratocarcinoma, cell line .a 34 to 865 10 to 845       836/882
(94 %)
13 diff
(98.6 %id)
TI_59379965   .a 34 to 936 96 to 1000       905/905
(100 %)
27 diff
(97.1 %id)
NM_004217.2   .a 34 to 1268 1 to 1235   RefSeq, AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 1235/1235
(100 %)
0 diff
(100 %id)
AB011446 liver and spleen .a 35 to 1198 7 to 1167       1161/1167
(99 %)
12 diff
(99.0 %id)
BM011072 brain, neuroblastoma, cell line .a 35 to 936 1 to 904       904/904
(100 %)
27 diff
(97.1 %id)
BU159680 eye, retinoblastoma .a 35 to 865 11 to 851       841/858
(98 %)
32 diff
(96.3 %id)
AL561428 B cells from Burkitt lymphoma .a 36 to 662 1 to 627   fully sequenced,   627/627
(100 %)
0 diff
(100 %id)
BQ055002 lymph, lymphoma, cell line .a 36 to 857 1 to 836       836/1121
(74 %)
39 diff
(96.6 %id)
AW245199 lung, small cell carcinoma .a 37 to 642 5 to 610     Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 606/610
(99 %)
6 diff
(99.1 %id)
BU162373 melanotic melanoma, cell line, skin .a 37 to 881 29 to 882       854/949
(89 %)
21 diff
(97.8 %id)
BU554119 ovary, teratocarcinoma, cell line .a 37 to 928 1 to 896       896/899
(99 %)
12 diff
(98.7 %id)
CX786328 human embryonic stem cells .a 37 to 819 1 to 783       783/783
(100 %)
0 diff
(100 %id)
TI_57238409   .a 37 to 820 23 to 811       789/811
(97 %)
13 diff
(98.4 %id)
AB011450   .a 38 to 1261 1 to 1224       1224/1224
(100 %)
2 diff
(99.9 %id)
BQ683601 melanotic melanoma, cell line, skin .a 38 to 924 1 to 894       894/943
(94 %)
22 diff
(97.7 %id)
BU848701 ovary, teratocarcinoma, cell line .a 39 to 910 1 to 880       880/894
(98 %)
12 diff
(98.7 %id)
AL524863 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .a 40 to 1078 1 to 1024       1024/1025
(99 %)
21 diff
(98.0 %id)
BF683384 leiomyosarcoma cell line, uterus .a 40 to 688 1 to 649       649/649
(100 %)
7 diff
(99.0 %id)
BF686240 leiomyosarcoma cell line, uterus .a 40 to 800 1 to 768       770/858
(89 %)
30 diff
(96.6 %id)
CR600836 neuroblastoma .a 41 to 1239 1 to 1199       1199/1199
(100 %)
0 diff
(100 %id)
CR604968 fetal liver .a 41 to 1202 1 to 1162       1162/1162
(100 %)
0 diff
(100 %id)
AL516276 brain, neuroblastoma, neuroblastoma cells .a 41 to 662 1 to 621   fully sequenced,   621/621
(100 %)
3 diff
(99.6 %id)
BX463217 fetal liver, Liver .a 41 to 955 1 to 912       912/988
(92 %)
5 diff
(99.5 %id)
BG329545 eye, retinoblastoma .a 41 to 857 1 to 817       820/841
(97 %)
36 diff
(95.8 %id)
BG329894 eye, retinoblastoma .a 41 to 781 1 to 744       746/935
(79 %)
24 diff
(97.5 %id)
BU553128 ovary, teratocarcinoma, cell line .a 41 to 743 25 to 729       705/947
(74 %)
16 diff
(98.4 %id)
CX166600 human embryonic stem cells differentiated toan early endodermal cell type .a 41 to 714 1 to 674       674/674
(100 %)
0 diff
(100 %id)
CX786561 human embryonic stem cells .a 41 to 787 1 to 747       747/747
(100 %)
0 diff
(100 %id)
BC080581 Lung, small cell carcinoma .a 42 to 1261 1 to 1220   available from MGC, AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 1220/1220
(100 %)
2 diff
(99.9 %id)
BE893523 melanotic melanoma, skin .a 42 to 771 1 to 743       743/1094
(67 %)
27 diff
(97.6 %id)
BU902604 leiomyosarcoma, uterus .a 42 to 901 1 to 864       864/868
(99 %)
11 diff
(98.8 %id)
BI912947 brain .a 43 to 820 1 to 783       783/783
(100 %)
6 diff
(99.3 %id)
BU162471 melanotic melanoma, cell line, skin .a 43 to 852 1 to 817       816/961
(84 %)
15 diff
(98.5 %id)
BU177888 melanotic melanoma, cell line, skin .a 43 to 910 1 to 882       882/915
(96 %)
26 diff
(97.2 %id)
BU185083 melanotic melanoma, cell line, skin .a 43 to 874 1 to 835       835/899
(92 %)
7 diff
(99.3 %id)
BQ684101 melanotic melanoma, cell line, skin .a 43 to 863 1 to 832       827/924
(89 %)
16 diff
(98.3 %id)
BQ056188 lymph, lymphoma, cell line .a 44 to 1012 1 to 982       982/1019
(96 %)
27 diff
(97.4 %id)
BX113445 liver and spleen .a 45 to 775 1 to 731       731/731
(100 %)
1 diff
(99.9 %id)
BU538446 adenocarcinoma, cell line, breast .a 47 to 781 1 to 742       742/1029
(72 %)
16 diff
(98.5 %id)
CN286710 embryonic stem cells, cell lines H1, H7, andH9 .a 48 to 318 13 to 284       272/284
(95 %)
7 diff
(97.6 %id)
BM009312 amelanotic melanoma, cell line, skin .a 50 to 730 1 to 682       682/685
(99 %)
20 diff
(97.1 %id)
BM013142 brain, neuroblastoma, cell line .a 50 to 781 1 to 738       738/869
(84 %)
12 diff
(98.7 %id)
TI_59382392   .a 50 to 781 102 to 839       738/869
(84 %)
12 diff
(98.7 %id)
H57656 liver and spleen .a 51 to 396 1 to 347       347/504
(68 %)
4 diff
(99.3 %id)
BM560845 amelanotic melanoma, cell line, skin .a 51 to 789 1 to 746       746/1166
(63 %)
15 diff
(98.8 %id)
TI_59384044   .a 51 to 730 59 to 739       681/684
(99 %)
19 diff
(97.3 %id)
BQ896714 hepatocellular carcinoma, cell line, Liver .a 52 to 763 1 to 716       716/914
(78 %)
17 diff
(98.2 %id)
BC009751 Lymph, Burkitt lymphoma .a 54 to 1268 1 to 1215   available from MGC, AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 1215/1215
(100 %)
0 diff
(100 %id)
BF219967 lung, small cell carcinoma .a 54 to 711 1 to 656       656/657
(99 %)
8 diff
(98.8 %id)
BE874500 large cell carcinoma, undifferentiated, lung .a 56 to 781 1 to 728       728/1165
(62 %)
20 diff
(98.3 %id)
BI226599 Burkitt lymphoma, lymph .a 58 to 856 5 to 802       798/802
(99 %)
5 diff
(99.4 %id)
BE253249 eye, retinoblastoma .a 61 to 782 1 to 717       717/723
(99 %)
15 diff
(98.0 %id)
BE621112 epithelioid carcinoma, Pancreas .a 63 to 722 1 to 661       661/666
(99 %)
11 diff
(98.4 %id)
BE264315 lung, small cell carcinoma .a 64 to 659 1 to 613       625/614
(101 %)
61 diff
(90.1 %id)
BE256245 eye, retinoblastoma .a 72 to 728 1 to 655       655/658
(99 %)
5 diff
(99.3 %id)
BE253568 eye, retinoblastoma .a 74 to 627 1 to 558       558/558
(100 %)
16 diff
(97.2 %id)
BE561223 Burkitt lymphoma, lymph .a 74 to 843 1 to 764       764/810
(94 %)
15 diff
(98.2 %id)
BG527876 lung, mucoepidermoid carcinoma .a 78 to 781 1 to 710       710/746
(95 %)
21 diff
(97.2 %id)
AB519677   .a 95 to 1129 1 to 1035       1035/1035
(100 %)
0 diff
(100 %id)
AF008552   .a 95 to 1129 1 to 1035       1035/1035
(100 %)
2 diff
(99.9 %id)
BT019534   .a 95 to 1127 1 to 1033       1033/1035
(99 %)
3 diff
(99.8 %id)
EL733399 mixed .a 95 to 758 1 to 663       663/663
(100 %)
1 diff
(99.9 %id)
TI_1948242476   .a 95 to 1128 135 to 1180       1046/1458
(71 %)
51 diff
(96.6 %id)
TI_1948242477   .a 95 to 1078 133 to 1133       1001/1404
(71 %)
69 diff
(95.1 %id)
TI_1948242763   .a 95 to 1118 134 to 1146       1013/1387
(73 %)
29 diff
(98.0 %id)
TI_1948242764   .a 95 to 1011 129 to 1036       908/1334
(68 %)
38 diff
(97.2 %id)
TI_1948243049   .a 95 to 1037 140 to 1077       938/1419
(66 %)
46 diff
(96.8 %id)
TI_1948243050   .a 95 to 781 129 to 817       689/1394
(49 %)
38 diff
(97.3 %id)
TI_1948243340   .a 95 to 1101 134 to 1136       1003/1426
(70 %)
23 diff
(98.4 %id)
TI_1948243341   .a 95 to 938 127 to 969       843/1396
(60 %)
38 diff
(97.3 %id)
BM456550 lymph, lymphoma, cell line .a 100 to 634 1 to 521       485/981
(49 %)
11 diff
(98.9 %id)
BU173439 leiomyosarcoma, uterus .a 100 to 947 1 to 861       861/861
(100 %)
16 diff
(98.2 %id)
BQ054552 lymph, lymphoma, cell line .a 106 to 959 1 to 856       856/1025
(83 %)
9 diff
(99.2 %id)
BE784021 eye, retinoblastoma .a 123 to 915 1 to 796       796/800
(99 %)
24 diff
(97.0 %id)
BG334902 melanotic melanoma, skin .a 130 to 708 1 to 579       579/581
(99 %)
3 diff
(99.5 %id)
BE791471 lung, small cell carcinoma .a 137 to 916 1 to 778       778/958
(81 %)
10 diff
(99.0 %id)
BF026292 melanotic melanoma, skin .a 151 to 959 1 to 801       801/987
(81 %)
19 diff
(98.1 %id)
CX872009 embryonic stem .a 199 to 873 1 to 675       675/675
(100 %)
0 diff
(100 %id)
BG119137 adenocarcinoma, cell line, Liver .a 209 to 818 1 to 609       609/610
(99 %)
2 diff
(99.7 %id)
CR591471 Neuroblastoma Cot 10-normalized .a 265 to 1242 1 to 978       978/978
(100 %)
0 diff
(100 %id)
AL521584 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .a 265 to 811 1 to 547   fully sequenced,   547/547
(100 %)
1 diff
(99.9 %id)
CB122662 Liver .a 268 to 717 1 to 450       450/450
(100 %)
0 diff
(100 %id)
AW405819 lymph .a 275 to 854 1 to 580       580/580
(100 %)
5 diff
(99.2 %id)
TI_154143200   .a 281 to 989 94 to 802       709/710
(99 %)
6 diff
(99.2 %id)
TI_1948243052   .a 486 to 1128 769 to 125       645/1391
(46 %)
14 diff
(99.0 %id)
BU193176 eye, retinoblastoma .a 487 to 1260 22 to 797       776/914
(84 %)
23 diff
(97.5 %id)
TI_1948243051   .a 487 to 1128 780 to 131       650/1297
(50 %)
32 diff
(97.6 %id)
TI_157600967   .a 488 to 1261 873 to 99   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 775/939
(82 %)
59 diff
(93.8 %id)
BG287721 bladder, transitional cell papilloma, cell line .a 499 to 1137 1 to 638       638/639
(99 %)
4 diff
(99.4 %id)
TI_1948242478   .a 516 to 1128 743 to 128       616/1313
(46 %)
19 diff
(98.6 %id)
BI225021 Burkitt lymphoma, lymph .a 518 to 1136 1 to 616       616/616
(100 %)
5 diff
(99.2 %id)
AI348029 adenocarcinoma, colon .a 523 to 1261 755 to 22   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 734/736
(99 %)
25 diff
(96.7 %id)
TI_1948243343   .a 523 to 1128 736 to 125       612/1365
(44 %)
15 diff
(99.0 %id)
BF516206   .a 528 to 1010 16 to 498     Submitted on the opposite strand 483/483
(100 %)
2 diff
(99.6 %id)
BX354691 Neuroblastoma Cot 25-normalized .a 533 to 1259 1 to 727   fully sequenced,   727/727
(100 %)
20 diff
(97.3 %id)
CR617702 Neuroblastoma Cot 25-normalized .a 534 to 1259 1 to 726       726/726
(100 %)
0 diff
(100 %id)
AI829974 lymph node, lymphoma, follicular mixed small and largecell .a 536 to 1262 726 to 2       725/726
(99 %)
5 diff
(99.4 %id)
CB146544 Liver .a 557 to 1147 1 to 591       591/591
(100 %)
1 diff
(99.9 %id)
BI912762 brain .a 567 to 1269 1 to 708       708/932
(75 %)
7 diff
(99.3 %id)
TI_57238218   .a 567 to 1269 35 to 742       708/966
(73 %)
13 diff
(98.7 %id)
BU632746 cell lines, Chondrosarcoma .a 573 to 1267 711 to 17   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 695/695
(100 %)
2 diff
(99.8 %id)
BU630787 cell lines, Chondrosarcoma .a 583 to 1261 697 to 19   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 679/679
(100 %)
2 diff
(99.8 %id)
BM989492 lung, Metastatic Chondrosarcoma .a 585 to 1261 696 to 19   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 678/678
(100 %)
3 diff
(99.6 %id)
BM972378 lung .a 585 to 1261 696 to 19   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 678/678
(100 %)
1 diff
(99.9 %id)
BU623756 cell lines, Enchondroma .a 587 to 1261 693 to 19   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 675/675
(100 %)
1 diff
(99.9 %id)
CD365809 Alveolar Macrophage, lung .a 587 to 1265 697 to 19   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 679/679
(100 %)
2 diff
(99.8 %id)
BE789326 large cell carcinoma, lung .a 589 to 1240 1 to 640       640/718
(89 %)
16 diff
(97.8 %id)
BU629451 cell lines, Chondrosarcoma .a 590 to 1261 691 to 19   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 673/673
(100 %)
7 diff
(99.0 %id)
AL516275 brain, neuroblastoma, neuroblastoma cells .a 601 to 1239 639 to 1   fully sequenced,   639/639
(100 %)
17 diff
(97.4 %id)
AL582638 B cells from Burkitt lymphoma .a 601 to 1230 627 to 1   fully sequenced,   627/627
(100 %)
35 diff
(94.5 %id)
BF220040 lung, small cell carcinoma .a 625 to 1190 581 to 16       566/581
(97 %)
0 diff
(100 %id)
CA422086 cell lines, Chondrosarcoma .a 676 to 1261 604 to 19   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 586/586
(100 %)
2 diff
(99.7 %id)
AW249658 lung, small cell carcinoma .a 700 to 1261 572 to 11   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 562/562
(100 %)
2 diff
(99.7 %id)
AA643652 colon, colon tumor RER+ .a 710 to 1214 549 to 48       502/549
(91 %)
13 diff
(97.7 %id)
BE392539 endometrium, adenocarcinoma cell line, uterus .a 719 to 1260 1 to 544       544/544
(100 %)
6 diff
(98.9 %id)
BM477585 leiomyosarcoma, uterus .a 734 to 1261 1 to 528   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 528/528
(100 %)
4 diff
(99.3 %id)
H81023 liver and spleen .a 739 to 1024 1 to 289   fully sequenced,   289/289
(100 %)
5 diff
(98.3 %id)
AW406366 lymph .a 743 to 1196 1 to 454       454/454
(100 %)
10 diff
(97.8 %id)
AA720659 germinal center B-cells, tonsil .a 746 to 1262 523 to 8       516/523
(98 %)
2 diff
(99.7 %id)
AL521583 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .a 750 to 1195 496 to 48   fully sequenced,   449/496
(90 %)
0 diff
(100 %id)
BX354690 Neuroblastoma Cot 25-normalized .a 750 to 1205 479 to 25   fully sequenced,   455/479
(94 %)
2 diff
(99.6 %id)
BX362457   .a 750 to 1227 478 to 1   fully sequenced,   478/478
(100 %)
2 diff
(99.6 %id)
TI_154143978   .a 750 to 1265 78 to 593       516/736
(70 %)
14 diff
(98.1 %id)
AA847804 germinal center B cell .a 758 to 1264 517 to 11   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 507/507
(100 %)
1 diff
(99.9 %id)
BI193863 epithelioid carcinoma cell line, Pancreas .a 763 to 1261 1 to 499   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 499/499
(100 %)
2 diff
(99.6 %id)
BX376736.
matches multiple genes
Neuroblastoma Cot 50-normalized .a 770 to 1262 1 to 492     also hits gene EIF3B 492/492
(100 %)
7 diff
(98.6 %id)
CN286705 embryonic stem cells, cell lines H1, H7, andH9 .a 771 to 1261 501 to 11   AAA Submitted on the opposite strand 491/491
(100 %)
2 diff
(99.6 %id)
AW236354 myeloid cells, 18 pooled CML cases, BCR/ABLrearrangement positive, includes both chronic phase andmyeloid blast crisis, whole blood .a 779 to 1124 346 to 1       346/355
(97 %)
35 diff
(90.2 %id)
AW339856 pooled .a 781 to 1260 482 to 1       482/526
(91 %)
21 diff
(96.1 %id)
AI830139 lung, squamous cell carcinoma, poorlydifferentiated (4 pooled tumors, including primary andmetastatic) .a 784 to 1261 472 to 1       472/474
(99 %)
25 diff
(94.8 %id)
BF740088 brain, glioblastoma (pooled) .a 792 to 1124 333 to 1       333/334
(99 %)
21 diff
(93.8 %id)
AI092097 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus .a 797 to 1262 461 to 1       461/461
(100 %)
11 diff
(97.7 %id)
AI348173 adenocarcinoma, colon .a 797 to 1118 322 to 1       322/322
(100 %)
24 diff
(92.6 %id)
AA807548 germinal center B cell .a 800 to 1261 491 to 34   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 458/458
(100 %)
6 diff
(98.7 %id)
AI039321   .a 803 to 1262 461 to 6       456/461
(98 %)
5 diff
(99.0 %id)
BU931850 ovary, teratocarcinoma, cell line .a 806 to 1261 1 to 456   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 456/456
(100 %)
2 diff
(99.6 %id)
BM988213 mixed .a 820 to 1261 460 to 19   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 442/442
(100 %)
2 diff
(99.6 %id)
AI803988 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus .a 826 to 1261 436 to 1       436/436
(100 %)
0 diff
(100 %id)
AI280182 adenocarcinoma, colon .a 829 to 1261 454 to 22   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 433/450
(96 %)
16 diff
(96.5 %id)
BF926662 nervous_tumor .a 836 to 1118 1 to 283       283/283
(100 %)
3 diff
(99.0 %id)
AA976765 pooled germ cell tumors .a 842 to 1262 422 to 1       422/422
(100 %)
8 diff
(98.2 %id)
BE045492 lymph node, lymphoma, follicular mixed small and largecell .a 845 to 1261 416 to 1       416/416
(100 %)
3 diff
(99.3 %id)
BG959821 colon .a 846 to 1262 10 to 425       416/491
(84 %)
7 diff
(98.6 %id)
H58497 liver and spleen .a 851 to 1259 419 to 4       416/422
(98 %)
8 diff
(98.2 %id)
BP431055   .a 853 to 1261 1 to 409       409/409
(100 %)
3 diff
(99.3 %id)
AW294622   .a 866 to 1261 414 to 18   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 397/397
(100 %)
3 diff
(99.3 %id)
AA883408 pooled .a 878 to 1124 247 to 1       247/250
(98 %)
7 diff
(97.2 %id)
DW009715 pooled .a 899 to 1150 1 to 252       252/255
(98 %)
7 diff
(97.3 %id)
W88963 liver and spleen .a 903 to 1262 362 to 3       360/362
(99 %)
0 diff
(100 %id)
AA810605 germinal center B cell .a 904 to 1261 404 to 49   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 356/359
(99 %)
11 diff
(97.0 %id)
CN286708 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 924 to 1261 1 to 338   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 338/338
(100 %)
2 diff
(99.5 %id)
DW411569 Liver .a 955 to 1260 16 to 321       306/328
(93 %)
6 diff
(98.2 %id)
AI453120 pooled .a 962 to 1262 306 to 6       301/306
(98 %)
0 diff
(100 %id)
H81024 liver and spleen .a 994 to 1255 263 to 1   fully sequenced,   263/263
(100 %)
0 diff
(100 %id)
AA738386 pooled germ cell tumors .a 1044 to 1262 219 to 1       219/219
(100 %)
0 diff
(100 %id)
BF752838 breast_normal .a 1074 to 1262 1 to 185       185/189
(97 %)
5 diff
(97.4 %id)
T25124   .a 1091 to 1262 174 to 3       172/174
(98 %)
0 diff
(100 %id)
AI352050 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus .a 1106 to 1261 156 to 1       156/156
(100 %)
0 diff
(100 %id)
AI802294   .a 1144 to 1262 123 to 5       119/123
(96 %)
0 diff
(100 %id)
C02095   .a 1194 to 1261 1 to 68       68/68
(100 %)
0 diff
(100 %id)
AW411256 muscle, rhabdomyosarcoma .b -9 to 698 1 to 708   available from MGC,   708/708
(100 %)
4 diff
(99.5 %id)
AW411425 muscle, rhabdomyosarcoma .b -9 to 641 3 to 654     Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 652/654
(99 %)
8 diff
(98.8 %id)
BG470446 eye, retinoblastoma .b 1 to 820 2 to 820       820/820
(100 %)
7 diff
(99.2 %id)
BG825692 muscle, rhabdomyosarcoma .b 1 to 907 2 to 901       903/940
(96 %)
29 diff
(97.0 %id)
BG826770 muscle, rhabdomyosarcoma .b 1 to 714 2 to 716       716/716
(100 %)
2 diff
(99.8 %id)
BC013300 Muscle, rhabdomyosarcoma .b 1 to 1248 1 to 1248 exact tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 1248/1248
(100 %)
0 diff
(100 %id)
ES308810 beard hair, skin .b 20 to 206 1 to 186       186/186
(100 %)
5 diff
(97.4 %id)
AA070237   .b 26 to 185 1 to 158       158/158
(100 %)
2 diff
(98.8 %id)
DR760310 embryonic stem .b 33 to 882 12 to 861       850/861
(98 %)
6 diff
(99.4 %id)
AA356271   .b 35 to 284 1 to 251       251/251
(100 %)
0 diff
(100 %id)
DW449651 Liver .b 72 to 253 11 to 202       202/202
(100 %)
56 diff
(72.3 %id)
TI_1948242765   .b 233 to 1115 1018 to 127       892/1357
(65 %)
19 diff
(98.6 %id)
TI_1948242766   .b 286 to 1115 953 to 123       831/1236
(67 %)
24 diff
(98.1 %id)
TI_1948243342   .b 288 to 1115 960 to 128       833/1304
(63 %)
21 diff
(98.4 %id)
AL530214 brain, neuroblastoma cells, Neuroblastoma Cot 50-normalized .b 289 to 1216 917 to 1       917/966
(94 %)
46 diff
(95.3 %id)
BX345089 Neuroblastoma Cot 50-normalized .b 291 to 1218 922 to 1       922/922
(100 %)
14 diff
(98.5 %id)
AA352701   .b 305 to 632 1 to 328       328/328
(100 %)
4 diff
(98.8 %id)
BU557887 adenocarcinoma, cell line, breast .b 312 to 1081 1 to 779       779/969
(80 %)
18 diff
(98.2 %id)
BM817524 Ascites, stomach .b 317 to 806 1 to 490       490/490
(100 %)
2 diff
(99.6 %id)
TI_57227882   .b 319 to 1146 54 to 876       823/824
(99 %)
9 diff
(99.0 %id)
BI868227 adenocarcinoma, cell line, Liver .b 320 to 1146 1 to 822       822/823
(99 %)
9 diff
(99.0 %id)
BM013076 brain, neuroblastoma, cell line .b 374 to 1173 1 to 815       815/905
(90 %)
24 diff
(97.4 %id)
TI_59382318   .b 375 to 1173 98 to 911   AAA   814/890
(91 %)
23 diff
(97.5 %id)
BI252965 hepatocellular carcinoma, cell line, Liver .b 398 to 1164 771 to 2       770/771
(99 %)
8 diff
(99.0 %id)
BM931055 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid .b 435 to 798 1 to 364   fully sequenced, Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 364/364
(100 %)
0 diff
(100 %id)
TI_149286982   .b 446 to 1248 885 to 84   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 802/1144
(70 %)
6 diff
(99.5 %id)
AW407129 lymph .b 451 to 767 1 to 316       316/316
(100 %)
4 diff
(98.8 %id)
BG333412 large cell carcinoma, lung .b 451 to 1179 1 to 729       729/729
(100 %)
7 diff
(99.1 %id)
TI_154144979   .b 458 to 1106 93 to 745       653/653
(100 %)
43 diff
(93.5 %id)
TI_154148243   .b 458 to 946 88 to 577       490/552
(88 %)
6 diff
(99.0 %id)
BP429197   .b 524 to 855 1 to 332       332/332
(100 %)
1 diff
(99.7 %id)
AA070238   .b 710 to 1248 541 to 1       541/541
(100 %)
6 diff
(98.9 %id)
BM684528 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid .b 737 to 1248 530 to 19   fully sequenced, AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 512/512
(100 %)
2 diff
(99.7 %id)
AW411426 muscle, rhabdomyosarcoma .b 755 to 1248 521 to 28   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 494/494
(100 %)
5 diff
(99.0 %id)
CB145143 Liver .c 1 to 373 1 to 373       373/373
(100 %)
1 diff
(99.8 %id)
CB143322 Liver .c 1 to 397 1 to 397   tiling clone,   397/397
(100 %)
0 diff
(100 %id)
CN286709 embryonic stem cells, DMSO-treated H9 cellline .c 273 to 1016 1 to 745   tiling clone,   745/745
(100 %)
5 diff
(99.4 %id)
BG502308 embryonal carcinoma, testis .d 1 to 699 1 to 700   tiling clone,   700/700
(100 %)
3 diff
(99.6 %id)
BG532619 embryonal carcinoma, testis .d 1 to 529 1 to 527       527/527
(100 %)
8 diff
(98.5 %id)
CN286701 embryonic stem cells, DMSO-treated H9 cellline .d 7 to 723 1 to 717       717/717
(100 %)
3 diff
(99.6 %id)
BF103573 embryonal carcinoma, testis .d 13 to 663 1 to 641       643/825
(77 %)
23 diff
(97.3 %id)
CN286707 embryonic stem cells, DMSO-treated H9 cellline .d 15 to 558 1 to 544       544/544
(100 %)
0 diff
(100 %id)
CA488263   .d 19 to 843 1 to 840       840/879
(95 %)
18 diff
(98.0 %id)
BU153790 eye, retinoblastoma .d 31 to 841 1 to 814       814/878
(92 %)
6 diff
(99.4 %id)
BM012583 brain, neuroblastoma, cell line .d 35 to 738 1 to 739       555/739
(75 %)
18 diff
(97.6 %id)
TI_59381803   .d 36 to 738 104 to 841       554/738
(75 %)
17 diff
(97.7 %id)
AB519678   .d 73 to 1011 1 to 939 exact tiling clone,   939/939
(100 %)
0 diff
(100 %id)
BE545822 cervical carcinoma cell line, cervix .d 125 to 838 1 to 709       709/834
(85 %)
8 diff
(99.1 %id)
BG777654 adenocarcinoma, Prostate .d 298 to 1062 1 to 753   tiling clone,   753/754
(99 %)
23 diff
(97.0 %id)
BM011901 brain, neuroblastoma, cell line .d 327 to 717 319 to 711       394/711
(55 %)
7 diff
(99.1 %id)
TI_59381084   .d 327 to 717 412 to 804       394/710
(55 %)
7 diff
(99.1 %id)
AA196900   .e 1 to 341 1 to 345   tiling clone,   345/354
(97 %)
25 diff
(93.0 %id)
AA196757   .e 950 to 1385 437 to 2   tiling clone,   436/437
(99 %)
1 diff
(99.8 %id)
BE514591 adenocarcinoma cell line, ovary .f 1 to 624 1 to 622   tiling clone,   622/623
(99 %)
5 diff
(99.2 %id)
CX784200 human embryonic stem cells .f 37 to 658 1 to 622       622/622
(100 %)
0 diff
(100 %id)
BU186069 epidermoid carcinoma, cell line, salivary gland .f 44 to 731 1 to 694       694/985
(70 %)
11 diff
(98.9 %id)
AK297976   .f 46 to 1212 1 to 1167 exact tiling clone,   1167/1167
(100 %)
0 diff
(100 %id)
DC358016   .f 46 to 615 1 to 570       570/570
(100 %)
0 diff
(100 %id)
CB128709 Liver .f 46 to 722 1 to 677       677/677
(100 %)
0 diff
(100 %id)
BP249622 Kidney .f 51 to 630 1 to 580       580/583
(99 %)
3 diff
(99.5 %id)
BP228463   .f 53 to 635 1 to 583       583/583
(100 %)
2 diff
(99.7 %id)
CB143577 Liver .f 53 to 536 1 to 484       484/484
(100 %)
1 diff
(99.8 %id)
CN286702 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .f 63 to 804 1 to 742       742/743
(99 %)
1 diff
(99.9 %id)
BG115183 duodenal adenocarcinoma, cell line, small intestine .f 64 to 582 1 to 526       526/945
(55 %)
12 diff
(98.8 %id)
BM013285 brain, neuroblastoma, cell line .f 66 to 851 1 to 800       766/801
(95 %)
32 diff
(96.1 %id)
TI_59380163   .f 66 to 851 102 to 901       766/801
(95 %)
32 diff
(96.1 %id)
BQ882273 eye, normal pigmented retinal epithelium .f 68 to 861 1 to 807       807/975
(82 %)
28 diff
(97.2 %id)
BG117695 adenocarcinoma, cell line, Liver .f 77 to 834 1 to 757       757/800
(94 %)
22 diff
(97.3 %id)
BG035071 adenocarcinoma, cell line, Liver .f 78 to 882 1 to 799       799/805
(99 %)
16 diff
(98.1 %id)
AL558477 T cells from T cell leukemia .g 1 to 974 1 to 977   tiling clone,   977/977
(100 %)
28 diff
(97.2 %id)
BU597365 mixed (pool of 40 RNAs) .g 194 to 1013 1 to 826   tiling clone,   826/826
(100 %)
10 diff
(98.8 %id)
BM905813 leiomyosarcoma, uterus .h 1 to 904 22 to 935 G210X K211E K212E V213G I214D ... tiling clone,   914/940
(97 %)
23 diff
(97.6 %id)
BG532483 embryonal carcinoma, testis .i 1 to 778 3 to 782   tiling clone,   782/783
(99 %)
16 diff
(98.0 %id)
CX781462 human embryonic stem cells .i 21 to 853 1 to 833 R229X tiling clone,   833/833
(100 %)
0 diff
(100 %id)
BF183143 large cell carcinoma, lung .i 37 to 812 1 to 759       762/763
(99 %)
37 diff
(95.2 %id)
BE731175 choriocarcinoma, placenta .j 1 to 811 1 to 807 C203S G204W T205H L206P D207G ... tiling clone,   807/1097
(73 %)
28 diff
(97.5 %id)
BX338749 Placenta Cot 25-normalized .k 1 to 948 1 to 934   tiling clone,   936/971
(96 %)
20 diff
(98.0 %id)
BP224663   .k 25 to 615 1 to 592       592/592
(100 %)
1 diff
(99.9 %id)
R97156 liver and spleen .k 49 to 417 12 to 387       376/466
(80 %)
18 diff
(96.2 %id)
FN114009 breast carcinoma .k 238 to 325 1 to 91       91/92
(98 %)
5 diff
(94.6 %id)
T25793   .k 688 to 822 1 to 134       134/134
(100 %)
4 diff
(97.1 %id)
DW450689 Liver .k 743 to 922 17 to 197   tiling clone,   181/197
(91 %)
10 diff
(95.0 %id)
FN143741 breast carcinoma .k 880 to 965 1 to 87   tiling clone,   87/90
(96 %)
5 diff
(94.5 %id)
BX373638 Placenta Cot 25-normalized .k 994 to 1474 482 to 1   tiling clone,   482/634
(76 %)
14 diff
(97.8 %id)
BF183879 bone marrow, from chronic myelogenous leukemia .l 1 to 661 1 to 653       653/896
(72 %)
18 diff
(98.0 %id)
BG613906 embryonal carcinoma, testis .l 1 to 662 1 to 674   tiling clone,   674/922
(73 %)
24 diff
(97.4 %id)
BP225027   .l 7 to 588 1 to 582       582/582
(100 %)
2 diff
(99.7 %id)
AU126835   .l 37 to 648 2 to 612   capped   611/613
(99 %)
5 diff
(99.2 %id)
BM757771 stomach .l 39 to 556 1 to 518       518/518
(100 %)
4 diff
(99.3 %id)
BM839006 stomach .l 39 to 544 1 to 506       506/506
(100 %)
4 diff
(99.3 %id)
BG616089 embryonal carcinoma, testis .l 42 to 649 1 to 617       617/893
(69 %)
18 diff
(98.0 %id)
BF211752 bone marrow, from chronic myelogenous leukemia .l 43 to 662 1 to 616       616/875
(70 %)
10 diff
(98.9 %id)
DA610247   .l 43 to 606 2 to 565   capped   564/564
(100 %)
1 diff
(99.9 %id)
CB113506 Liver .l 44 to 600 1 to 557       557/557
(100 %)
1 diff
(99.9 %id)
CB137591 Liver .l 44 to 615 1 to 572       572/572
(100 %)
0 diff
(100 %id)
CB142452 Liver .l 44 to 556 1 to 513       513/513
(100 %)
0 diff
(100 %id)
CB148529 Liver .l 44 to 604 1 to 561       561/561
(100 %)
1 diff
(99.9 %id)
BP315742 mammary gland .l 44 to 625 1 to 582   tiling clone,   582/582
(100 %)
0 diff
(100 %id)
BM849844 myeloma .l 44 to 591 1 to 548       548/548
(100 %)
0 diff
(100 %id)
DA004823   .l 45 to 609 2 to 566   capped   565/565
(100 %)
1 diff
(99.9 %id)
BP263944 small intestine .l 45 to 619 1 to 575       575/575
(100 %)
5 diff
(99.2 %id)
CD246638 embryonic stem cells, WA01, passage 38 .l 46 to 595 24 to 578       555/919
(60 %)
14 diff
(98.5 %id)
BM845066 lymph node, stomach .l 50 to 603 1 to 554       554/554
(100 %)
0 diff
(100 %id)
CN286706 embryonic stem cells, DMSO-treated H9 cellline .l 53 to 547 2 to 497       496/497
(99 %)
6 diff
(98.8 %id)
AW248441 lung, small cell carcinoma .l 54 to 575 14 to 535       522/535
(97 %)
6 diff
(98.9 %id)
AF004022   .l 57 to 1291 1 to 1234 E161M Q167H S169T A182R D183I ... tiling clone, AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 1234/1234
(100 %)
9 diff
(99.3 %id)
AF015254   .l 57 to 1291 1 to 1234 R14D Q15K E161M D183V H184M ...     1234/1234
(100 %)
14 diff
(98.9 %id)
BG388261 embryonal carcinoma, cell line, testis .l 63 to 558 1 to 497       497/497
(100 %)
10 diff
(98.0 %id)
AW951023   .l 72 to 647 1 to 576       576/576
(100 %)
19 diff
(96.8 %id)
BE264602 lung, small cell carcinoma .l 73 to 595 1 to 527       527/804
(65 %)
17 diff
(97.9 %id)
N49806 liver and spleen .l 244 to 661 1 to 422       422/425
(99 %)
10 diff
(97.7 %id)
H51697 liver and spleen .l 518 to 901 1 to 386   tiling clone,   386/389
(99 %)
7 diff
(98.3 %id)
TI_227715337   .l 578 to 1295 815 to 101   AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 715/927
(77 %)
10 diff
(99.0 %id)
N49700 liver and spleen .l 774 to 1291 520 to 1       520/522
(99 %)
9 diff
(98.3 %id)
AU149613   .l 952 to 1288 337 to 1       337/339
(99 %)
9 diff
(97.4 %id)
BM466907 eye, retinoblastoma .m 1 to 705 39 to 744 L184V C200W V210G N212E F215P ... tiling clone,   706/1129
(62 %)
20 diff
(98.3 %id)
BU595757 mixed (pool of 40 RNAs) .n 1 to 910 5 to 748 A53I R54L K56Y K57A S58P ... tiling clone, Suspected internal deletion 748/829
(90 %)
20 diff
(97.6 %id)
BF184817 bone marrow, from chronic myelogenous leukemia .o 1 to 552 1 to 554   tiling clone,   556/694
(80 %)
22 diff
(96.9 %id)
BM755984 Ascites, stomach .o 8 to 550 1 to 543   tiling clone,   543/546
(99 %)
6 diff
(99.0 %id)
H82884 liver and spleen .o 33 to 393 1 to 369       369/425
(86 %)
9 diff
(97.9 %id)
BU181480 eye, retinoblastoma .o 35 to 906 11 to 887 exact tiling clone,   877/887
(98 %)
14 diff
(98.5 %id)
H82885 liver and spleen .o 825 to 1182 368 to 3   tiling clone,   364/368
(98 %)
6 diff
(98.4 %id)
BI199088 brain, neuroblastoma .p 1 to 633 1 to 632   tiling clone,   632/632
(100 %)
13 diff
(98.0 %id)
BE887353 leiomyosarcoma, uterus .p 6 to 758 1 to 748 N111K E112R T113L Y114S R115P ... tiling clone,   748/883
(84 %)
28 diff
(96.9 %id)
DW412663 Liver .q -9 to 305 9 to 323   tiling clone,   315/323
(97 %)
5 diff
(98.5 %id)
BE797606 lung, small cell carcinoma .q 248 to 940 124 to 815 I38M R40V P41L L42W G43A ... tiling clone,   784/888
(88 %)
16 diff
(98.2 %id)
CN286703 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .r 1 to 450 1 to 450   tiling clone,   450/450
(100 %)
5 diff
(98.9 %id)
AI174768 Liver .r 12 to 474 119 to 581       463/469
(98 %)
8 diff
(98.3 %id)
BX372960 Neuroblastoma Cot 50-normalized .r 62 to 694 636 to 1 E3K D6N V16G I17D H18S ...     636/773
(82 %)
11 diff
(98.6 %id)
BF111283 pooled .r 66 to 696 647 to 17 E2K E3K C11* AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 631/689
(91 %)
9 diff
(98.7 %id)
CD618195   .r 72 to 398 16 to 341       326/356
(91 %)
6 diff
(98.4 %id)
CV337943 nervous_tumor .r 79 to 501 1 to 423       423/423
(100 %)
4 diff
(99.1 %id)
AA297276   .r 94 to 410 1 to 318       318/318
(100 %)
3 diff
(99.1 %id)
AW170452 cervix, tumor .r 100 to 696 597 to 1   tiling clone,   597/597
(100 %)
5 diff
(99.2 %id)
BM797588 Ascites, stomach .r 101 to 471 1 to 371       371/371
(100 %)
3 diff
(99.2 %id)
DA429872 colon .s 1 to 553 2 to 554 exact tiling clone, capped   553/553
(100 %)
0 diff
(100 %id)
CB161184 Liver .t 1 to 554 1 to 554 exact tiling clone,   554/554
(100 %)
0 diff
(100 %id)
AY677083   .u 1 to 900 1 to 900 exact tiling clone,   900/900
(100 %)
0 diff
(100 %id)
AB519679   .u 2 to 900 1 to 899 exact     899/899
(100 %)
0 diff
(100 %id)
BU157783 ductal carcinoma, cell line, Pancreas .va 1 to 799 1 to 816 exact tiling clone,   816/946
(86 %)
28 diff
(97.1 %id)
CN286704 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .vb 1 to 661 5 to 665 exact tiling clone,   665/665
(100 %)
1 diff
(99.9 %id)
BU156559 leiomyosarcoma, uterus .vc 1 to 748 1 to 754 G43X D45I H46M G47E G48E ... tiling clone,   754/872
(86 %)
18 diff
(98.0 %id)
CD698570 normal nasopharynx .vd -8 to 457 16 to 481   tiling clone,   466/481
(96 %)
6 diff
(98.8 %id)
BU599323 mixed (pool of 40 RNAs) .vd 1 to 476 3 to 480       480/785
(61 %)
5 diff
(99.4 %id)
BM836155 stomach .vd 3 to 364 1 to 362       362/362
(100 %)
4 diff
(98.9 %id)
BM835941 stomach .vd 3 to 480 1 to 479       479/481
(99 %)
8 diff
(98.4 %id)
BM836047 stomach .vd 5 to 368 1 to 364       364/364
(100 %)
4 diff
(99.0 %id)
CB145136 Liver .vd 8 to 394 1 to 387       387/387
(100 %)
2 diff
(99.5 %id)
BP353219   .vd 8 to 588 1 to 582       582/582
(100 %)
1 diff
(99.9 %id)
CN286711 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .vd 19 to 476 1 to 458       458/458
(100 %)
3 diff
(99.4 %id)
AA071235   .vd 21 to 480 1 to 462       460/472
(97 %)
11 diff
(97.7 %id)
CX167288 human embryonic stem cells differentiated toan early endodermal cell type .vd 24 to 834 1 to 811       811/811
(100 %)
0 diff
(100 %id)
BG472452 eye, retinoblastoma .vd 25 to 480 1 to 457       457/461
(99 %)
5 diff
(99.0 %id)
AL550823 placenta, Placenta Cot 25-normalized .vd 26 to 871 1 to 844   tiling clone, fully sequenced,   844/844
(100 %)
2 diff
(99.8 %id)
AL121492 melanoma (MeWo cell line) .vd 26 to 408 1 to 384       384/384
(100 %)
1 diff
(99.8 %id)
R97911 liver and spleen .vd 29 to 480 1 to 461     Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 461/470
(98 %)
19 diff
(96.0 %id)
CX784469 human embryonic stem cells .vd 29 to 646 1 to 618       618/618
(100 %)
0 diff
(100 %id)
AL574583 placenta, Placenta Cot 25-normalized .vd 841 to 1513 671 to 2   tiling clone, fully sequenced,   670/671
(99 %)
12 diff
(98.3 %id)
AA071486   .vd 1033 to 1542 514 to 1   tiling clone,   514/514
(100 %)
10 diff
(98.1 %id)
R97912 liver and spleen .vd 1181 to 1542 382 to 20   tiling clone, AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 363/363
(100 %)
2 diff
(99.5 %id)
N76832 liver and spleen .ve-u 1 to 269 1 to 268   tiling clone,   268/269
(99 %)
5 diff
(98.2 %id)
AW978991   .ve-u 148 to 663 515 to 1 L24X tiling clone, Submitted on the opposite strand 515/515
(100 %)
7 diff
(98.7 %id)
AA831014 germinal center B cell .ve-u 208 to 620 412 to 2 W10V Y12T G13A R14D Q15R ...     411/412
(99 %)
0 diff
(100 %id)
AA825706 germinal center B cell .ve-u 208 to 610 401 to 1 Y12T G13A R14D Q15R T16R ...     401/401
(100 %)
3 diff
(99.3 %id)
N55457 liver and spleen .ve-u 315 to 664 358 to 1       358/473
(75 %)
12 diff
(97.5 %id)
AW139028   .ve-u 465 to 664 217 to 18   tiling clone, AAA Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) 200/200
(100 %)
1 diff
(99.5 %id)
AA081819   .ve-u 490 to 665 1 to 174   fully sequenced,   174/174
(100 %)
6 diff
(96.6 %id)
AA112247   .ve-u 509 to 628 127 to 8   fully sequenced,   120/127
(94 %)
0 diff
(100 %id)
AI200065 lung Gene AURKB, variant not shown         Suspected internal deletion, this clone was ignored    
AI953453 normal epithelium, ovary Gene AURKB, variant not shown         This clone was ignored    
BE257599 eye, retinoblastoma Gene AURKB, variant not shown         Suspected internal deletion, this clone was ignored    
BF055549 pooled Gene AURKB, variant not shown         Suspected internal deletion, this clone was ignored    
BG472202 eye, retinoblastoma Gene AURKB, variant not shown         Suspected internal deletion, this clone was ignored    
BM017583 astrocytoma grade IV, cell line, brain Gene AURKB, variant not shown         This clone was ignored    
BM910592 astrocytoma grade IV, cell line, brain Gene AURKB, variant not shown         This clone was ignored    
BU509270 leiomyosarcoma, uterus Gene AURKB, variant not shown         This clone was ignored    
TI_59388087   Gene AURKB, variant not shown         This clone was ignored    
? Gene Summary Gene on genome mRNA:.a, .b, .c, .d, .e, .f, .g, .h, .i, .j, .k, .l, .m, .n, .o, .p, .q, .r, .s, .t, .u, .va, .vb, .vc, .vd, .ve-u Alternative mRNAs features, proteins, introns, exons, sequences Expression Tissue Function, regulation, related genes DCI